Previous 10 | Next 10 |
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-03-01 08:29:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more. ...
2024-02-26 16:45:21 ET Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q4 2023 Earnings Call Feb 26, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings...
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects operating profit in 2024, approaching ...
SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...
2024-02-23 13:15:39 ET More on BioCryst Pharmaceuticals BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely Analyzing BioCryst's Position Amid Pharvaris' HAE Breakthrough BioCryst falls after Pharvaris win for hereditary angioedema drug BioCry...
2024-02-23 11:24:29 ET Major earnings expected before the bell on Monday include: BioCryst Pharmaceuticals ( BCRX ) Berkshire Hathaway ( BRK.B ) Domino's Pizza ( DPZ ) Elanco Animal Health ( ELAN ) Li Auto ( LI ) Read the full article on See...
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO ® (berotralstat) that showed patients who initiated ORLADEYO experienced rapid, substantial a...
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO ® (berotralstat) for the rou...
2024-02-18 14:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...